Certified Global Research Member
Key Questions Answered
- Global Market Outlook
- In-depth analysis of global and regional trends
- Analyze and identify the major players in the market, their market share, key developments, etc.
- To understand the capability of the major players based on products offered, financials, and strategies.
- Identify disrupting products, companies, and trends.
- To identify opportunities in the market.
- Analyze the key challenges in the market.
- Analyze the regional penetration of players, products, and services in the market.
- Comparison of major players’ financial performance.
- Evaluate strategies adopted by major players.
- Recommendations
Why Choose Market Research Future?
- Vigorous research methodologies for specific market.
- Knowledge partners across the globe
- Large network of partner consultants.
- Ever-increasing/ Escalating data base with quarterly monitoring of various markets
- Trusted by fortune 500 companies/startups/ universities/organizations
- Large database of 5000+ markets reports.
- Effective and prompt pre- and post-sales support.
The lower gastrointestinal (GI) series market is impacted by its basic job in diagnosing and assessing different gastrointestinal problems. As a demonstrative imaging technique, the lower GI series gives important experiences into the lower some portion of the gastrointestinal system, aiding in the location of conditions like colorectal cancer growth, polyps, and infalmmatory bowel illness.
The market is driven by the predominance of colorectal diseases, including colorectal malignant growth, diverticulitis, and Crohn's condition. The rising frequency of these circumstances, especially in aging populations, highlights the significance of the lower GI series as a symptomatic device, adding to market growth.
The emphasis on early discovery of colorectal disease through screening programs decidedly influences the lower GI series market. Healthcare drives and awareness campaigns elevating customary screenings add to expanded patient awareness and doctor suggestions for lower GI series assessments, reinforcing market interest.
The symptomatic precision and clinical viability of the lower GI series assume a vital part in its market elements. Doctors esteem the system for its capacity to give detailed pictures of the lower gastrointestinal parcel, aiding in the exact analysis of conditions and illuminating suitable treatment plans.
Patient inclinations and solace during analytic strategies influence the market for lower GI series. Endeavors to upgrade patient experience through superior imaging methods, diminished technique times, and insignificant distress add to expanded patient acknowledgment and the general market advance.
The availability and improvement of healthcare foundation assume a part in the directness and usage of the lower GI series. Regions with deep rooted healthcare offices and imaging focuses are probably going to observe higher reception rates, while endeavors to extend healthcare foundation impact market growth in creating regions.
Repayment strategies and healthcare financial aspects essentially impact the market elements of lower GI series. The availability of positive repayment plans for the methodology influences its reasonableness and accessibility, affecting the dynamic interaction for both healthcare suppliers and patients.
Covered Aspects:
| Report Attribute/Metric | Details |
|---|---|
| Growth Rate | Â Â 7.15% (2024-2032) |
Lower GI Series Market Highlights:
Lower GI Series Market Overview
Lower GI Series Market Size was valued at USD 248.46 Billion in 2023. The Global Lower GI Series industry is projected to grow from USD 268.11 Billion in 2024 to USD 478.3 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.15% during the forecast period (2024 - 2032).
Lower GI series is a lower gastrointestinal series or barium enema; it is one of the medical procedure, which helps in diagnosis of diseases and abnormalities related to human large intestine and rectum. Moreover, major companies are focusing on investment in R&D to introduce efficient methods as well as innovative devices since they are under constant pressure to provide new and cost-effective methods.
According to the National Institute of Diabetes and Digestive and Kidney Diseases, approximately 60-70 million people are affected by either major or minor GIT diseases in America. The number is continuously increasing due to poor diet and increasing aging population. The lower GI series market is driven majorly due to increasing prevalence of GI diseases, gastric cancer, and changing lifestyle. Additionally, developing technologies, increasing cost-effective methods, and the government’s support for research have boosted the growth of this market. However, availability of alternative therapies may hamper the growth of the market during the review period.
Lower GI Series Market Segmentation
The lower GI series market is segmented on the basis of by applications, types of tests, and end user.
On the basis of applications, it is segmented into gastroenteritis, colon polyps, tumor, strictures crohn's disease, ulcerative colitis, and others.
On the basis of types of test, it is segmented into double-contrast test and single-contrast test.
On the basis of end users, this market is segmented into hospitals, clinics, and laboratories.
Regional Analysis of the Lower GI Series Market
On the regional basis, the market is segmented into the America, Europe, Asia Pacific, and the Middle East & Africa. The America owns a significant share in the global market as a result of huge investment in research and development in the healthcare sector and its strong economic conditions for research and development. Increasing patient base and geriatric population to boost the growth of the Lower GI Series Market.
Europe is the second largest market followed by Asia Pacific on account of increasing technological improvements. The technological improvements will result in higher efficiency and accuracy for diagnosis. Asia Pacific is the fastest growing market due to increasing prevalence of communicable diseases in this region. India and China have started investing in research and development of healthcare sector, which will boost the Lower GI Series Market growth of this region.
Key Players in the Lower GI Series Market
Some of the key players in Lower GI Series Market are:
- Eisai (US)
- Cadila Pharmaceuticals
- PeaceHealth
- Purdue Pharma L.P.
- Alfa Wassermann
- NOVADAQ
- Mount Sinai Beth Israel
- AstraZeneca
- Ironwood Pharmaceuticals Inc.
Intended Audience
- Manufacturing industries
- Pharmaceutical industry
- Biotechnology companies
- Research and development (R&D) companies
- Government research laboratories
- Medical research institutes
Leading companies partner with us for data-driven Insights
Kindly complete the form below to receive a free sample of this Report
Tailored for You
- Dedicated Research on any specifics segment or region.
- Focused Research on specific players in the market.
- Custom Report based only on your requirements.
- Flexibility to add or subtract any chapter in the study.
- Historic data from 2014 and forecasts outlook till 2040.
- Flexibility of providing data/insights in formats (PDF, PPT, Excel).
- Provide cross segmentation in applicable scenario/markets.
